CRDF Q2 2023 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108,000+18.7% YoY

Gross Profit

$108,000100.0% margin

Operating Income

-$12M-11303.7% margin

Net Income

-$11M-10324.1% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+30.1%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$97M

Total Liabilities

$11M

Stockholders' Equity

$87M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108,000	$91,000	+18.7%
Gross Profit	$108,000	$91,000	+18.7%
Operating Income	-$12M	-$10M	-16.9%
Net Income	-$11M	-$10M	-6.8%